Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorCohen, Jeffrey A
dc.contributor.authorBermel, Robert
dc.contributor.authorGrossman, Cynthia
dc.contributor.authorHersh, Carrie
dc.contributor.authorHyland, Megan
dc.contributor.authorMowry, Ellen
dc.contributor.authorTintore Subirana, Mar
dc.contributor.authorZabalza de Torres, Ana
dc.contributor.authorMontalban Gairín, Xavier
dc.date.accessioned2022-09-07T12:14:43Z
dc.date.available2022-09-07T12:14:43Z
dc.date.issued2022-06
dc.identifier.citationCohen JA, Bermel RA, Grossman CI, Hersh CM, Hyland M, Mowry EM, et al. Immunoglobulin G immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within Multiple Sclerosis Partners Advancing Technology and Health Solutions. Mult Scler J. 2022 Jun;28(7):1131–7.
dc.identifier.issn1477-0970
dc.identifier.urihttp://hdl.handle.net/11351/8057
dc.descriptionMultiple sclerosis; SARS-COV-2 vaccination; Humoral immune response
dc.description.abstractBackground: The impact of multiple sclerosis (MS) disease-modifying therapies (DMTs) on SARS-CoV-2 vaccination response is uncertain. Methods: Post-SARS-CoV-2 vaccination blood samples across multiple DMTs were tested for SARS-CoV-2 immunoglobulin G (IgG) response. Results: Three hundred twenty-two people with MS were included; 91.9% received an mRNA vaccine. Post-vaccination reactive IgG rates (IgG index > 1) were 40% for anti-CD20 (32/80 patients); 41% for sphingosine 1-phosphate receptor modulators (S1PRM, 16/39); and 100% for all other classes, including the no DMT group. Conclusion: Anti-CD20 therapies and S1PRMs reduce IgG response to SARS-CoV-2 vaccination; IgG response is preserved with other DMTs.
dc.language.isoeng
dc.publisherSAGE Publications
dc.relation.ispartofseriesMultiple sclerosis Journal;28(7)
dc.rightsAttribution-NonCommercial 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/
dc.sourceScientia
dc.subjectEsclerosi múltiple - Tractament
dc.subjectImmunoglobulina G
dc.subjectCOVID-19 (Malaltia) - Vacunació
dc.subject.meshImmunoglobulin G
dc.subject.meshMultiple Sclerosis
dc.subject.meshViral Vaccines
dc.titleImmunoglobulin G immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within Multiple Sclerosis Partners Advancing Technology and Health Solutions
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1177/13524585211061343
dc.subject.decsinmunoglobulina G
dc.subject.decsesclerosis múltiple
dc.subject.decsvacunas víricas
dc.relation.publishversionhttps://doi.org/10.1177/13524585211061343
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Cohen JA, Bermel RA] Mellen Center, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA. [Grossman CI] Biogen, Cambridge, MA, USA. [Hersh CM] Lou Ruvo Center for Brain Health, Cleveland Clinic, Las Vegas, NV, USA. [Hyland M] Department of Neurology, University of Rochester Medical Center, Rochester, NY, USA. [Mowry EM] Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. [Tintorè M, Zabalza A, Montalban X] Servei de Neurologia i Neuroimmunologia, Centre d’Esclerosi Múltiple de Catalunya (CEMCAT), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain
dc.identifier.pmid34994577
dc.identifier.wos000740936300001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record